Some of the world known research and publications
This is all the data we have been able to find related to the connection between histamines and SARS-Cov-2 virus that causes Covid-19 as well as the possible beneficial
effects of antihistamines within an early treatment protocol.
Azelastine - update 2021
CEBINA reports positive findings on the potency of azelastine, a widely used anti-histamine, as anti-COVID-19 approach.
CEBINA identifie un vaporisateur nasal antihistaminique courant comme potentielle approche anti-COVID-19.
Cardiovascular complications are rapidly emerging as a key threat in coronavirus disease 2019 (COVID-19) in addition to respiratory disease. The mechanisms underlying the disproportionate effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with cardiovascular comorbidities, however, remain incompletely understood.
Histamine intolerance results from a disequilibrium of accumulated histamine and the capacity for histamine degradation. Histamine is a biogenic amine that occurs to various degrees in many foods. In healthy persons, dietary histamine can be rapidly detoxified by amine oxidases, whereas persons with low amine oxidase activity are at risk of histamine toxicity...
Reports that the over-the-counter histamine H2 receptor antagonist famotidine could help treat the novel coronavirus disease (COVID-19) appeared from April 2020. We, therefore, examined reports on interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and histamine receptor antagonists...
A team of scientists from the United Kingdom has recently revealed the therapeutic benefits of histamine receptor antagonists in reducing long-term symptoms of coronavirus disease 2019 (COVID-19).
This study is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of cetirizine and famotidine in reducing the duration of symptoms in patients with COVID-19. Secondary aims are to determine if cetirizine and famotidine decrease severity and duration of symptoms, incidence of hospitalizations, ICU admissions, and death.
•Early cardiac pathology likely caused by vasoconstriction ischemia then anoxia
•Ischemia and anoxia possibly caused by vasoconstriction of cardiac pericyte cells
•Vasoconstrictions likely caused by histamine or SARS-CoV-2 pericyte infection